David Ricks, Eli Lilly CEO (Photographer: Jeenah Moon/Bloomberg via Getty Images)
August 8, 2024 01:38 PM EDT
Pharma

Lil­ly says to ‘take some cau­tion’ on oth­er com­pa­nies’ ear­ly-stage obe­si­ty da­ta, calls out com­pounders

Kyle LaHucik

Senior Reporter

Af­ter post­ing a blowout quar­ter of fi­nan­cial re­sults, Eli Lil­ly has al­most made the obe­si­ty busi­ness look easy. But amid in­vestors’ en­thu­si­asm …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times